New Seeking Alpha write up
Axsome Therapeutics: Positive Q3, We Like The Launch Success Story
Nov 27, 2023 10:41 AM | Axsome Therapeutics, Inc.(AXSM) | By: BiotechValley Insights
Axsome Therapeutics reports robust Q3 earnings with record revenue of $57.8 million, driven by sales of flagship product Auvelity.
The company plans to expand its sales force to deepen market penetration and reach a broader base of prescribers and patients.
Axsome's diversified portfolio and strategic positioning in the specialty pharmaceutical market position it well for sustained growth.
We maintain a buy rating on AXSM.